Cancer Cells Killed by Copper Wake Up the Immune System to Fight Back
Killing cancer cells with copper may do more than just eliminate them: early research suggests the process triggers an immune alarm that could revive stalled immunotherapy.
Immunotherapy has transformed oncology, but a stubborn problem remains: many tumors simply stop responding to it. New preclinical research from The University of Texas MD Anderson Cancer Center now points toward an unexpected ally in that fight, copper. A study published in the journal Cell on June 22, 2026 found that a copper-triggered form of cell death not only destroys cancer cells directly but also sets off an immune alarm that could restore sensitivity to immunotherapy in resistant tumors.
Cuproptosis Activates Immune Cells to Attack Tumors
The research, led by Boyi Gan, Ph.D., professor of Experimental Radiation Oncology at MD Anderson, centers on cuproptosis, a form of regulated cell death distinct from better-known pathways like apoptosis or necroptosis. When copper ions accumulate inside a cell, they interfere with mitochondrial respiration and cause proteotoxic stress, ultimately killing the cell. The molecular mechanism of cuproptosis involves a mitochondrial reductase called FDX1 (ferredoxin 1), which reduces copper and drives its interaction with enzymes in the TCA cycle, triggering a cascade of protein aggregation and cell death.
What Gan's team discovered is that this process does not happen in isolation. Cuproptotic cancer cells release damage-associated molecular patterns (DAMPs), molecular distress signals that activate dendritic cells and, in turn, recruit CD8-positive T cells, the immune system's primary tumor-killing force. Crucially, the relationship runs in both directions: those same CD8-positive T cells then make surviving cancer cells more susceptible to cuproptosis. The result is a self-reinforcing cycle where copper-induced death and immune activation amplify each other.
Immunotherapy-Resistant Tumors Respond to the Combination
The most clinically significant finding is what happened when Gan's team combined cuproptosis-inducing treatment with anti-PD-L1 immunotherapy in preclinical animal models. Tumor growth slowed significantly, and, critically, the combination worked even in models that had been resistant to immunotherapy alone. This suggests the immune activation triggered by cuproptosis may be strong enough to overcome the mechanisms that typically allow tumors to evade checkpoint blockade.
The practical implications hinge on the agents used to induce cuproptosis. As Gan noted, the compounds used in the study already have clinical experience and favorable safety profiles, which means the path from preclinical finding to human trial may be shorter than it would be with entirely novel drugs. "These findings may offer a practical path toward developing new combination treatments for patients whose cancers no longer respond to immunotherapy," Gan said.
How the Team Built the Evidence
Cuproptosis was first named and characterized by Tsvetkov et al. in 2022, building on earlier work from 2019 that identified a copper-dependent cell death pathway. Gan's team extended that foundation by systematically investigating the two-way relationship between cuproptosis and the immune system, using animal models to test whether the immune activation was real, durable, and capable of overcoming resistance.
Their preclinical design involved comparing outcomes in models treated with cuproptosis-inducing agents alone, anti-PD-L1 therapy alone, and the combination. The fact that the combination outperformed each individual arm in resistant models is what gives the result its weight, though it remains essential to note this is animal-model data and has not yet been tested in humans.
Open Questions About Clinical Translation and Tumor Diversity
The study is explicitly preclinical, and the challenges facing cuproptosis-based therapies in broader development are real: functional modulation of copper delivery, reducing systemic toxicity, and contending with the heterogeneity of tumors across patients and cancer types all remain unsolved problems. Different tumors express different levels of the key molecular players, and a treatment optimized for one cancer subtype may need substantial recalibration for another.
The FDX1 gene, which encodes the mitochondrial reductase central to cuproptosis, emerged as a potential biomarker in the study. Higher FDX1 expression was linked to better treatment responses, raising the possibility of stratifying patients before treatment. But validating a biomarker requires prospective clinical data, and that work lies ahead. Researchers also need to establish optimal dosing regimens, determine which cancer types are most likely to respond, and gather long-term safety data across diverse populations.
The Next Step Toward Clinical Trials
The road from a compelling preclinical result to an approved combination therapy is long, but the MD Anderson findings add serious momentum to a growing field. Nanomedicine-based approaches to cuproptosis immunotherapy are already being explored as a way to deliver copper more precisely to tumors while sparing healthy tissue, which could eventually address some of the toxicity concerns that complicate systemic copper delivery.
For patients who have exhausted standard immunotherapy options, the prospect of a combination strategy that reawakens immune sensitivity is significant. The funding behind this work, from the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, and institutional grants from MD Anderson, reflects how seriously the research community is taking the cuproptosis-immunity axis. Whether the self-reinforcing cycle of copper-induced death and immune activation translates into durable human responses will ultimately depend on the clinical trials that this study is designed to motivate.
Evidence rating
INVESTIGATIONAL — 65/100
Preclinical study using animal tumor models only; no human participants. Demonstrates a mechanistic causal chain between cuproptosis signaling, CD8+ T cell activation, and anti-PD-L1 synergy, but results cannot be extrapolated to clinical outcomes without human trials. Findings have not yet been independently replicated.
References
- Copper-induced cell death stimulates antitumor immune cell responses. https://www.news-medical.net/news/20260622/Copper-induced-cell-death-stimulates-antitumor-immune-cell-responses.aspx
- Shuhui Wang, Jian Zhang, Yanyan Zhou (2026). Cuproptosis: Biomarkers, Mechanisms and Treatments in Diseases. Molecules. https://doi.org/10.3390/molecules31030394
- Qingbo Feng, Chenyu Huo, Maijian Wang, Handong Huang, Xingbin Zheng, Ming Xie (2024). Research progress on cuproptosis in cancer. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2024.1290592
- Yan Wang, Yunfei Zhu, Yanxin Wang, Yutong Liu, Pengfei Wang, Mingkun Yu (2026). Cuproptosis at the Crossroads of Tumor Microenvironment Inflammation and Metabolic Rewiring Mechanisms and Therapeutic Opportunities. Mediators of Inflammation. https://doi.org/10.1155/mi/2952331
- Maoshan Wang, Chunyu Shi, Zhenbo Shu, Zhongmin Li (2026). Cuproptosis-triggering nanomedicine boosts antitumor immunotherapy. Theranostics. https://doi.org/10.7150/thno.123080
